MALT lymphoma: Many roads lead to nuclear factor-κb activation

Histopathology

Volumn 58, Issue 1, 2011, Pages 26-38

  Du, Ming Qing ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

A20; API2 MALT1; BCL10; MALT lymphoma; MALT1; NF B

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; B LYMPHOCYTE RECEPTOR; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN BETA RECEPTOR; PROTEIN BCL 10; PROTEIN KINASE C; PROTEIN P52; RECEPTOR INTERACTING PROTEIN 140; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN;

CELL ADHESION; CELL CYCLE REGULATION; CHROMOSOME TRANSLOCATION; CYLINDROMA; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE ACTIVATION; GENE CONTROL; GENE DELETION; GENE MUTATION; GENE TARGETING; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

APOPTOSIS; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MODELS, GENETIC; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 78851471359     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03699.x     Document Type: Review

References (110)

1. Rawlings DJ, Sommer K, Moreno-Garcia ME. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat. Rev. Immunol. 2006; 6; 799-812.
2. Thome M, Weil R. Post-translational modifications regulate distinct functions of CARMA1 and BCL10. Trends Immunol. 2007; 28; 281-288.
3. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 2004; 14; 289-301.
4. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004; 4; 499-511.
5. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-kappaB regulatory pathways. Annu. Rev. Biochem. 2009; 78; 769-796.
6. Sun SC. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 2008; 8; 501-511.
7. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol. 2008; 29; 469-478.
8. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J. Biol. Chem. 2009; 284; 8217-8221.
9. Du MQ, Atherton JC. Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. Gut 2006; 55; 886-893.
10. Du MQ. MALT lymphoma: recent advances in aetiology and molecular genetics. J. Clin. Exp. Hematop. 2007; 47; 31-42.
11. Willis TG, Jadayel DM, Du MQ et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96; 35-45.
12. Zhang Q, Siebert R, Yan M et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat. Genet. 1999; 22; 63-68.
13. Ruland J, Duncan GS, Elia A et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 2001; 104; 33-42.
14. Xue L, Morris SW, Orihuela C et al. Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells. Nat. Immunol. 2003; 4; 857-865.
15. Yan M, Lee J, Schilbach S, Goddard A, Dixit V. mE10, a novel caspase recruitment domain-containing proapoptotic molecule. J. Biol. Chem. 1999; 274; 10287-10292.
16. Koseki T, Inohara N, Chen S et al. CIPER, a novel NF kappaB-activating protein containing a caspase recruitment domain with homology to Herpesvirus-2 protein E10. J. Biol. Chem. 1999; 274; 9955-9961.
17. Thome M, Martinon F, Hofmann K et al. Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappaB transcription factor and c-Jun N-terminal kinase. J. Biol. Chem. 1999; 274; 9962-9968.
18. Srinivasula SM, Ahmad M, Lin JH et al. CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappaB activation and apoptosis. J. Biol. Chem. 1999; 274; 17946-17954.
19. Tian MT, Gonzalez G, Scheer B, DeFranco AL. Bcl10 can promote survival of antigen-stimulated B lymphocytes. Blood 2005; 106; 2105-2112.
20. Gaide O, Martinon F, Micheau O et al. Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation(1). FEBS Lett. 2001; 496; 121-127.
21. Bertin J, Wang L, Guo Y et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J. Biol. Chem. 2001; 276; 11877-11882.
22. McAllister-Lucas LM, Inohara N, Lucas PC et al. Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction. J. Biol. Chem. 2001; 276; 30589-30597.
23. Lucas PC, Yonezumi M, Inohara N et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J. Biol. Chem. 2001; 276; 19012-19019.
24. Liu Y, Dong W, Chen L et al. BCL10 mediates lipopolysaccharide/toll-like receptor-4 signaling through interaction with Pellino2. J. Biol. Chem. 2004; 279; 37436-37444.
25. Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J. Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production. Proc. Natl Acad. Sci. USA 2007; 104; 134-138.
26. Wang D, You Y, Lin PC et al. Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors. Proc. Natl Acad. Sci. USA 2007; 104; 145-150.
27. Bhattacharyya S, Borthakur A, Tyagi S et al. B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation. J. Biol. Chem. 2010; 285; 522-530.
28. Costanzo A, Guiet C, Vito P. c-E10 is a caspase-recruiting domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-kappaB. J. Biol. Chem. 1999; 274; 20127-20132.
29. Li Z, Wang H, Xue L et al. Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma. Blood 2009; 114; 4158-4168.
30. Kuo SH, Yeh PY, Chen LT et al. Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood 2008; 112; 2927-2934.
31. Ye H, Dogan A, Karran L et al. BCL10 expression in normal and neoplastic lymphoid tissue: nuclear localization in MALT lymphoma. Am. J. Pathol. 2000; 157; 1147-1154.
32. Liu H, Ye H, Dogan A et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001; 98; 1182-1187.
33. Maes B, Demunter A, Peeters B, Wolf-Peeters C. BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression. Blood 2002; 99; 1398-1404.
34. Ye H, Liu H, Attygalle A et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 2003; 102; 1012-1018.
35. Hu S, Du MQ, Park SM et al. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J. Clin. Invest. 2006; 116; 174-181.
36. Nakagawa M, Hosokawa Y, Yonezumi M et al. MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10. Blood 2005; 106; 4210-4216.
37. Ye H, Gong L, Liu H et al. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J. Pathol. 2005; 205; 293-301.
38. Yeh PY, Kuo SH, Yeh KH et al. A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus. J. Biol. Chem. 2006; 281; 167-175.
39. Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 2003; 302; 1581-1584.
40. Ruland J, Duncan GS, Wakeham A, Mak TW. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003; 19; 749-758.
41. Tusche MW, Ward LA, Vu F et al. Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J. Exp. Med. 2009; 206; 2671-2683.
42. Uren GA, O'Rourke K, Aravind L et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol. Cell 2000; 6; 961-967.
43. Noels H, Van Loo G, Hagens S et al. A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions. J. Biol. Chem. 2007; 282; 10180-10189.
44. Kawadler H, Gantz MA, Riley JL, Yang X. The paracaspase MALT1 controls caspase-8 activation during lymphocyte proliferation. Mol. Cell 2008; 31; 415-421.
45. Su H, Bidere N, Zheng L et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 2005; 307; 1465-1468.
46. Rebeaud F, Hailfinger S, Posevitz-Fejfar A et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat. Immunol. 2008; 9; 272-281.
47. Coornaert B, Baens M, Heyninck K et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat. Immunol. 2008; 9; 263-271.
48. Duwel M, Welteke V, Oeckinghaus A et al. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J. Immunol. 2009; 182; 7718-7728.
49. Dierlamm J, Baens M, Wlodarska I et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93; 3601-3609.
50. Akagi T, Motegi M, Tamura A et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18; 5785-5794.
51. Morgan JA, Yin Y, Borowsky AD et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res. 1999; 59; 6205-6213.
52. Lucas PC, Kuffa P, Gu S et al. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene 2007; 26; 5643-5654.
53. Baens M, Fevery S, Sagaert X et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res. 2006; 66; 5270-5277.
54. Garrison JB, Samuel T, Reed JC. TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 2009; 28; 1584-1593.
55. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat. Rev. Cancer 2004; 4; 644-653.
56. Hosokawa Y, Suzuki H, Nakagawa M, Lee TH, Seto M. API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-kappaB activation. Biochem. Biophys. Res. Commun. 2005; 334; 51-60.
57. Zhou H, Du MQ, Dixit VM. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005; 7; 425-431.
58. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19; 652-658.
59. Wlodarska I, Veyt E, De Paepe P et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19; 1299-1305.
60. Fenton JA, Schuuring E, Barrans SL et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosom. Cancer 2006; 45; 164-168.
61. Hu H, Wang B, Borde M et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat. Immunol. 2006; 7; 819-826.
62. Brown PJ, Ashe SL, Leich E et al. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 2008; 111; 2816-2824.
63. Novak A, Akasaka T, Manske M et al. Elevated expression of GPR34 and its association with a novel translocation t(X;14)(p11;q32) involving IGHS and GPR34 in MALT lymphoma. Blood 2008; 112; 785.
64. Vinatzer U, Gollinger M, Mullauer L et al. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin. Cancer Res. 2008; 14; 6426-6431.
65. Chanudet E, Ye H, Ferry J et al. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J. Pathol. 2009; 217; 420-430.
66. Kim WS, Honma K, Karnan S et al. Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma. Genes Chromosom. Cancer 2007; 46; 776-783.
67. Honma K, Tsuzuki S, Nakagawa M et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosom. Cancer 2008; 47; 1-7.
68. Chanudet E, Huang Y, Ichimura K et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010; 24; 483-487.
69. Novak U, Rinaldi A, Kwee I et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009; 113; 4918-4921.
70. Kato M, Sanada M, Kato I et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459; 712-716.
71. Compagno M, Lim WK, Grunn A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459; 717-721.
72. Schmitz R, Hansmann ML, Bohle V et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. 2009; 206; 981-989.
73. Honma K, Tsuzuki S, Nakagawa M et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114; 2467-2475.
74. Vereecke L, Beyaert R, Van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009; 30; 383-391.
75. Graham RR, Cotsapas C, Davies L et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 2008; 40; 1059-1061.
76. Dieguez-Gonzalez R, Calaza M, Perez-Pampin E et al. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res. Ther. 2009; 11; R42.
77. Plenge RM, Cotsapas C, Davies L et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat. Genet. 2007; 39; 1477-1482.
78. Musone SL, Taylor KE, Lu TT et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 2008; 40; 1062-1064.
79. Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun. Rev. 2010; 9; 195-199.
80. Boone DL, Turer EE, Lee EG et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 2004; 5; 1052-1060.
81. Thome M, Tschopp J. TCR-induced NF-kappaB activation: a crucial role for Carma1, Bcl10 and MALT1. Trends Immunol. 2003; 24; 419-424.
82. Lee EG, Boone DL, Chai S et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289; 2350-2354.
83. Ott G, Katzenberger T, Greiner A et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res. 1997; 57; 3944-3948.
84. Auer IA, Gascoyne RD, Connors JM et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann. Oncol. 1997; 8; 979-985.
85. Zhou Y, Ye H, Martin-Subero JI et al. Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). Br. J. Haematol. 2006; 133; 35-42.
86. Ho L, Davis RE, Conne B et al. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005; 105; 2891-2899.
87. Hamoudi RA, Appert A, Ye H et al. Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 2010; 24; 1487-1497.
88. Sagaert X, Theys T, Wolf-Peeters C, Marynen P, Baens M. Splenic marginal zone lymphoma-like features in API2-MALT1 transgenic mice that are exposed to antigenic stimulation. Haematologica 2006; 91; 1693-1696.
89. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342; 571-574.
90. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J. Pathol. 1996; 178; 122-127.
91. Greiner A, Knorr C, Qin Y et al. Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation. Am. J. Pathol. 1997; 150; 1583-1593.
92. Hussell T, Isaacson PG, Crabtree JE, Dogan A, Spencer J. Immunoglobulin specificity of low grade B cell gastrointestinal lymphoma of mucosa-associated lymphoid tissue (MALT) type. Am. J. Pathol. 1993; 142; 285-292.
93. D'Elios MM, Amedei A, Manghetti M et al. Impaired T-cell regulation of B-cell growth in Helicobacter pylori-related gastric low-grade MALT lymphoma. Gastroenterology 1999; 117; 1105-1112.
94. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298; 2199-2202.
95. Craig VJ, Cogliatti SB, Arnold I et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia 2010; 24; 1186-1196.
96. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001; 194; 1861-1874.
97. Feuerhake F, Kutok JL, Monti S et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106; 1392-1399.
98. Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 2003; 198; 851-862.
99. Savage KJ, Monti S, Kutok JL et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102; 3871-3879.
100. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 2005; 23; 630-639.
101. Hinz M, Lemke P, Anagnostopoulos I et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J. Exp. Med. 2002; 196; 605-617.
102. Horie R. NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma. Int. Rev. Immunol. 2007; 26; 269-281.
103. Lam LT, Davis RE, Pierce J et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin. Cancer Res. 2005; 11; 28-40.
104. Ngo VN, Davis RE, Lamy L et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441; 106-110.
105. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007; 109; 2700-2707.
106. Lenz G, Davis RE, Ngo VN et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319; 1676-1679.
107. Davis RE, Ngo VN, Lenz G et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463; 88-92.
108. Annunziata CM, Davis RE, Demchenko Y et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12; 115-130.
109. Keats JJ, Fonseca R, Chesi M et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12; 131-144.
110. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J. Pathol. 2010; 221; 248-263.